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Abstract
Background: Although never evaluated for efficacy, n–3 (v-3) long-chain polyunsaturated fatty acids (LCPUFAs) are
commercially offered as treatment for irritable bowel syndrome (IBS).
Objective: This study was designed to investigate, in a mast cell–dependent model for visceral hypersensitivity, whether
this pathophysiologic mechanism can be reversed by dietary LCPUFA treatment via peroxisome proliferator-activated
receptor g (PPARG) activation.
Methods: Maternally separated rats were subjected to hypersensitivity-inducing acute stress at adult age. Reversal was
attempted by protocols with tuna oil–supplemented diets [4% soy oil (SO) and 3% tuna oil (SO–T3) or 3% SO and 7% tuna oil
(SO–T7)] and compared with control SO diets (7% or 10% SO) 4 wk after stress. The PPARG agonist rosiglitazone was
evaluated in a 1 wk preventive protocol (30 mg  kg21  d21). Erythrocytes were assessed to confirm LCPUFA uptake and
tissue expression of lipoprotein lipase and glycerol kinase as indicators of PPARG activation. Colonic mast cell
degranulation was evaluated by toluidine blue staining. In vitro, human mast cell line 1 (HMC-1) cells were pretreated with
rosiglitazone, eicosapentaenoic acid, or docosahexaenoic acid, stimulatedwith phorbol 12-myristate 13-acetate (PMA) and
calcium ionophore or compound 48/80 and evaluated for tumor necrosis factor a (TNF-a) and b-hexosaminidase release.
Results: Stress led to visceral hypersensitivity in all groups. Hypersensitivity was not reversed by SO–T3 or control treatment
[prestress vs. 24 h poststress vs. posttreatment area under the curve; 766 4 vs. 1286 12 (P < 0.05) vs. 1156 14 and 826 5
vs. 1276 16 (P < 0.01) vs. 1136 19, respectively]. Comparison of SO–T7with its control showed similar results [746 6 vs. 103
6 13 (P < 0.05) vs. 1156 17 and 666 3 vs. 1036 10 (P < 0.05) vs. 1176 11, respectively]. Erythrocytes showed significant
LCPUFA uptake in the absence of colonic PPARG activation. Rosiglitazone induced increased PPARG target gene expression,
but did not prevent hypersensitivity. Mast cell degranulation never differed between groups. Rosiglitazone and LCPUFAs
significantly reduced PMA/calcium ionophore–induced TNF-a release but not degranulation of HMC-1 cells.
Conclusion: Dietary LCPUFAs did not reverse stress-induced visceral hypersensitivity in maternally separated rats.
Although further research is needed, claims concerning LCPUFAs as a treatment option in IBS cannot be confirmed at this
point and should be regarded with caution. J Nutr 2015;145:915–22.
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Introduction
Dietary supplementation with n–3 long-chain polyunsaturated
fatty acids (LCPUFAs)9 has been demonstrated to elicit potential
health effects ranging from decreased blood pressure in hyper-
tension and cardiovascular disease to a decrease in inflammation
in rheumatoid arthritis, inflammatory bowel disease, and asthma
(1). Whereas n–3 FAs are thought to act in an anti-inflammatory
manner, n–6 FAs are generally considered to be proinflammatory.
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The latter is in particular attributed to the role of n–6 arachidonic
acid (AA) and its proinflammatory metabolites (2). In humans
consuming a typicalWestern diet, the membrane phospholipids of
blood inflammatory cells contain substantial amounts of AA
(usually 10–20% of FAs), whereas the amounts of n–3 EPA
(usually 0.5–1% of FAs) and DHA (usually 2–4%) are much lower
(3–6). This shift toward n–6 PUFAs is thought to play a role in a
variety of diseases (7), and it has recently been shown in female
patients suffering from irritable bowel syndrome (IBS) (8). Presently,
the beneficial effects of LCPUFAs in IBS treatment are often
discussed on patient internet forums; despite the absence of scientific
evidence of efficacy, LCPUFA preparations are sold online as a
treatment option for this disorder (Internet search: ‘‘omega, IBS’’).
IBS is a gastrointestinal disorder that affects ;11% of the
global population (9). Patients experience abdominal pain or
discomfort associated with changes in bowel habits without a
structural explanation (10). Although the prevalence and socio-
economic impact of IBS are high, the pipeline for novel drugs,
especially those targeting abdominal pain, is limited. Visceral
hypersensitivity, measured by an enhanced response to colonic
distension, is considered an important pathophysiologic mecha-
nism to explain abdominal pain. Indications are that stress-
induced mast cell degranulation is an important trigger for
visceral hypersensitivity (11). Admittedly, most of these data were
obtained in animal models and their validity for IBS is sometimes
questioned (12). However, in patient biopsies, mast cells were
shown to be in closer proximity to colonic nerve endings, and this
was shown to correlate with severity and frequency of abdominal
pain (13). Further, supernatants from patient-derived mucosal
biopsies were shown to release mast cell mediators capable of
activating intestinal nerves in ex vivo settings (14, 15). In a clinical
trial, we showed that treatment with the mast cell stabilizer and
histamine-1 receptor antagonist ketotifen successfully increased
the threshold of discomfort (meaning lowered sensitivity to
colonic distension) and decreased other symptoms in hypersen-
sitive IBS patients (16). Based on these trial results, we next
evaluated the peripherally restricted histamine-1 receptor antag-
onists ebastine and fexofenadine in the rat maternal separation
model for IBS. Both antihistaminics reversed poststress visceral
hypersensitivity in rats (17) More recently, van Wanrooij et al.
(18) translated these results into a successful double-blind
randomized control trial. In concert, these results suggest that
the activation of colonic mast cells and subsequent activation of
sensory afferents bymast cell mediators plays an important role in
visceral hypersensitivity and IBS symptom generation.
Although current knowledge of the effects of n–3 LCPUFAs on
mast cell activation is limited, dietary supplementation of n–3
LCPUFAs has proven beneficial in several other diseases in which
mast cells are thought to be relevant, e.g., rheumatoid arthritis,
asthma, and allergic disorders (1–3, 7, 19, 20). In addition, in
in vitro experiments, treatment with different n–3 LCPUFAs,
including marine n–3 EPA and DHA, reduced both the produc-
tion and release of a variety of mast cell mediators (21–23). The
immune modulatory actions of n–3 LCPUFAs are elicited via
several mechanisms, including competition with AA for the
2-acyl position of membrane phospholipids, thereby influencing
concentrations of metabolites and/or hormones that regulate the
behavior of cells. In addition, n–3 LCPUFAs activate nuclear
peroxisome proliferator-activated receptor g (PPARG), which
negatively regulates inflammatory cytokine production by
interfering with the activation of transcription factors (1).
Importantly, PPARG agonists also reduce the production and
release of histamine by mast cells (24, 25). Moreover, in the rat
maternal separation model, we showed reversal of poststress
visceral hypersensitivity with 2 different histamine-1 receptor
antagonists (17). These data indicate that dietary n–3 LCPUFA
supplementation may prove beneficial, possibly via PPARG-
mediated mast cell modulation, in IBS. Given the current internet
attention and premature commercialization of the LCPUFA
hypothesis in relation to IBS, preclinical studies addressing this
hypothesis are eagerly awaited. Thus, we investigated whether
dietary supplementation with marine n–3 LCPUFAs, in the form of
tuna oil, could reverse poststress hypersensitivity to colonic
distension in the maternal separation model.
Methods
Ethics statement. All procedures were conducted in accordance with
institutional guidelines and were approved by the Animal Ethical
Committee of the Academic Medical Center at the University of
Amsterdam (reference protocol number 100998).
Rats. Long-Evans rats (Harlan, Horst) were bred and housed at the
animal facility of the Academic Medical Center in Amsterdam under
conditions of controlled light (0600–1800), temperature (20–22C), and
humidity (45%). Water and food were consumed by the rats ad libitum.
Maternal separation. In earlier papers (26–28), we demonstrated that
when subjected to maternal separation, Long-Evans rats showed an
enhanced response to colorectal distension upon acute stress [i.e., water
avoidance (WA)] later in life. In contrast, when nonhandled rats were
subjected to the same acute stressor at an adult age, they did not become
hypersensitive to distension. In the present investigation, we only evaluated
maternally separated rats. On postnatal day 2, female pups were removed
from the litter and dams were separated from the remaining pups for 3 h
daily for a 12 d period (postnatal days 2–14) as described earlier (28).
Measurement of the visceromotor response to colonic distension
and data analysis. In IBS patients, investigations of visceral sensitivity
are performed by colorectal distensions: hypersensitive patients perceive
pain during luminal distensions at lower volumes or pressures than
normal controls. During distensions, pain scores in patients are often
evaluated by self-rating questionnaires (i.e., visual analogue score) that
cannot be assessed in rats. However, colorectal distension in rats leads to
reproducible contractions of abdominal musculature—the so-called
visceromotor response—and the quantification of these contractions by
electromyography is often used to assess visceral pain. In the present
investigation, we assessed abdominal electyromyography signals during
distension protocols (1, 1.5, and 2 mL) by radiotelemetry. For details on
colonic distensions, telemetric-tracing methodology, and data analysis,
please refer to earlier papers (17, 26–28).
Experimental protocol and diet composition. The soy oil (SO)
source of the cow milk protein–free AIN-93G diet (29) (Research Diet
Services) was partially replaced by tuna oil (Bioriginals), the FA
composition of which is shown in Table 1. In group 1, 10 rats were
fed a 4% SO and 3% tuna oil (SO–T3) diet. In group 2, which was paired
with group 1, 8 control rats were fed a 7% SO diet. In group 3, 9 rats
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received a 3% SO and 7% tuna oil (SO–T7) diet. In group 4, which was
paired with group 3, 8 control rats were fed a 10% SO diet. In the latter
2 groups, an increase in the total fat percentage was needed to meet
the requirements for an adequate amount and balance of the essential
FAs Ala and linoleic acid (18:2n–6) (29); an appropriate amount of
cornstarch thus was replaced by extra fat. Diets were stored at 220C
and refreshed weekly. Rats from all 4 groups were fed the tuna-oil–
enriched or control diet post-WA only. Before dietary LCPUFA admin-
istration, intervention rats were fed a standard Combined Rat and
Mouse-expanded (CRM-E) diet (Special Diet Services, Technilab-BMI).
The approximate composition of the CRM-E diet was 10% moisture,
3% crude oil, 18.6% crude protein, 4.1% crude fiber, 5.8% ash, and
57.6% nitrogen-free extract. Distensions and concurrent electromyog-
raphy recordings were performed 30 min before WA stress, 24 h post-
WA, and on days 2, 8, and 28 or 29 post-WA. During WA, rats were
positioned on a pedestal surrounded by water for 1 h (28).
Because symptoms are already present in IBS patients, we usually
prefer post-WA treatment, with the purpose of reducing visceral hyper-
sensitivity. However, when testing the possibility of activating PPARG to
modulate visceral hypersensitivity, we chose a prestress treatment with a
pharmacologic PPARG agonist to reach maximal efficacy. Rosiglitazone
(30 mg  kg21  d21; Sigma-Aldrich) was added to a ground CRM-E
unpurified diet, which was then converted into pellets. For the control rats,
pellets were made from nonsupplemented CRM-E unpurified feed. Rats
were fed these diets for a 7 d period pre-WA. In this experiment, distensions
and concurrent electromyography recordings were performed before
dietary treatment, 30 min before WA stress, and 24 h post-WA.
Erythrocyte FA profile. Immediately after rats were killed with the use
of CO2 inhalation, blood was collected with the use of heart puncture in
lithium-heparin–coated blood tubes. Plasma and cells were separated
with the use of centrifugation at 10003 g for 15 min at 4C. Erythrocytes
were stored at280C until analysis. Lipids were extracted as described by
Bligh and Dyer (30). The relative membrane FA compositionwas analyzed
with the use of GC as described previously (31).
Histochemistry. Mucosal mast cells were stained following a staining
protocol described by Wingren and Enerba¨ck (32). Distal colon paraffin
sections (4 mm thickness) were incubated for 6 d in toluidine blue in
0.5 mol/L hydrochloric acid (pH 0.5). To semiquantitatively assess mast
cell activation, every fifth section, with a total of 5 sections per rat, was
evaluated in a blinded manner. A total of 50 mast cells were counted per
section, and each mast cell was categorized as either dark staining
intensity, medium staining intensity, or light staining intensity, with
lightly stained mast cells indicating degranulation and dark stained cells
representing nondegranulated mast cells.
Reverse transcriptase qPCR. Total RNA was isolated from white
adipose tissue or the distal colon of rats treated with rosiglitazone and
vehicle, or the SO–T7 and its control SO group, respectively, with the use
of TriPure (Roche Diagnostics) and following the manufacturers
protocol. After deoxyribonuclease treatment, cDNA was obtained with
the use of the RevertAid First Strand cDNA Synthesis Kit (Fermentas).
qPCR was performed with SYBR Green in a LightCycler480 system
(Roche) with the use of a default 60C program. Primer pairs used are
detailed in Supplemental Table 1.
In vitro mast cell TNF-a release and colonic TNF-a, Il-1b, and
Il-6 concentrations. PPARG activation is known to interfere with
NF-kB signaling and TNF-a is one of the genes regulated by NF-kB
activation (33, 34). Therefore, and because mast cells are a major source
of intestinal TNF-a (35), in order to evaluate the effects of EPA (20:5n–3),
DHA (22:6n–3), and rosiglitazone on mast cell cytokine release, we used
TNF-a as the prototype NF-kB–dependent cytokine. We evaluated TNF-
a in human mast cell line 1 (HMC-1) cell culture supernatants. HMC-
1 cells [humanmast cell line kindly provided by Dr. Butterfield (36)] were
pretreated with rosiglitazone, DHA, or EPA, which were all dissolved in
DMSO, for 30 min. Concentrations used ranged from 0 to100 mM for
rosiglitazone and 0 to 50 mM for DHA and EPA where indicated.
Controls were pretreated with equal volumes of DMSO alone (1% final
concentration). Next, cells were stimulated with a combination of phorbol
12-myristate 13-acetate (25 ng  mL21) and calcium ionophore A23187
(0.5 mM) for 4 h. The different EPA and DHA experimental conditions
were tested in triplicate, rosiglitazone conditions in sextuplicate. Super-
natant was analyzed with the use of a human TNF-a ELISA (R&D
Systems). In addition, rat distal colons were homogenized in Green Berger
Lysis buffer with added protease inhibitor cocktail (Sigma-Aldrich) with
the use of Tissue Lyzer (Qiagen). Cytokine concentrations were deter-
mined with the use of rat TNF-a, Il-1b, and Il-6 ELISAs (R&D Systems).
In vitro mast cell degranulation. As a readout for mast cell
degranulation, we used the b-hexosaminidase assay that is often used
as a marker enzyme for histamine-containing granules [described earlier
(23)]. In short, HMC-1 cells were pretreated with different concentra-
tions of rosiglitazone (0–100 mM), DHA (0–50 mM), or EPA (0–50 mM),
and then stimulated with compound 48/80 (1 mg  mL21; Sigma-
Aldrich). The different EPA and DHA experimental conditions were
tested in sextuplicate, rosiglitazone conditions in nonuplicate. Upon
centrifugation, supernatants were collected and remaining cell pellets
were lysed with Triton X-100. Supernatants and cell pellets were then
incubated with 4-methylumbelliferyl glucosaminidase, and release of
fluorescent 4-methylumbelliferone was measured as the readout for b-
hexosaminidase activity (release calculated as a percentage of total
cellular content).
Statistical analysis. The analysis was performed with the use of SPSS
for Windows version 16.0. The normality and homogeneity distribution
of data were assessed with Bartlett¨s test. Data concerning the viscer-
omotor response to colonic distension and in vitro b-hexosaminidase
and TNF-a release by HMC-1 cells were subjected to log transformation
and analyzed statistically with the use of 2-factor repeated measures
ANOVA followed by Bonferronis multicomparison post hoc test. Data
regarding reverse transcriptase qPCR, toluidine blue mast cell staining,
in vivo cytokine concentrations, and FAs were analyzed with the use of
the Mann–Whitney U test for independent samples. In all cases,
differences were considered to be significant when P # 0.05. Data in
all figures are presented untransformed as means 6 SEMs.
Results
Effects of dietary n–3 LCPUFAs on visceral hypersensitivity
and mucosal mast cell activation. WA stress significantly
increased the visceromotor response to colorectal distension in all
experimental and control groups (Figure 1A and 1C). Similar to SO
control diets, dietary treatment with the SO–T3 (Figure 1A) or the
SO–T7 (Figure 1C) diet did not reverse post-WA hypersensitivity.
Colonic tissue sections were used to establish mast cell activation
status in a semiquantitative manner by evaluating toluidine blue
staining intensity of mucosal mast cells. When comparing tuna oil
diets with respective control diets, we observed no differences
between the percentages of cells scored in the 3 staining intensity
categories (Figure 1B and 1D).
TABLE 1 FA composition of tuna oil batch used to partially
replace the soy oil source of the AIN-93G diet in SO–T3 and
SO–T7 diets1
FA Value, g/100 g FA
SFA 27.8
MUFA 20.4
PUFA 39.4
n–6 PUFA 5.6
n–3 PUFA 33.8
EPA 6.2
DHA 24.7
1 SO–T3, 4% soy oil and 3% tuna oil; SO–T7, 3% soy oil and 7% tuna oil.
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LCPUFAs induced changes in erythrocyte FA profile.
Compared with those of rats fed the control diet, in rats fed
SO–T3 or SO–T7 diets, the relative content of EPA and DHA in
the erythrocyte membrane was significantly increased (Figure
2A, 2B, 2D, and 2E). Importantly, in rats fed SO–T7, the relative
content of AA (20:4n–6) in the erythrocyte membrane was
significantly decreased (Figure 2F). Rats fed SO–T3 showed no
significant changes in relative AA content compared to control
7% SO diet (Figure 2C).
Effects of rosiglitazone-mediated PPARG activation on
visceral hypersensitivity and mucosal mast cell activation.
Comparison of pretreatment and pre-WA measurements did
not show significant rosiglitazone-induced changes in base-
line sensitivity to distension. Subsequent WA stress signifi-
cantly increased the visceromotor response in rats fed the
rosiglitazone-supplemented diet, as well as in control rats
(Figure 3A). In accordance with these sensitivity results, treatment
with rosiglitazone did not affect mucosal mast cell activation
(Figure 3B).
Dietary LCPUFAs and rosiglitazone administration induced
mRNA expression of PPARG target genes. We investigated
the expression of lipoprotein lipase and glycerol kinase, 2 target
genes of PPARG that are involved in lipid metabolism. mRNA
expression of both genes was significantly increased in the
abdominal fat tissue of rats treated with rosiglitazone compared
with control rats (Figure 3C and 3D), but not in the colonic
tissue of rats fed the SO–T7 diet (Figure 3E and 3F).
In vivo release of TNF-a, Il-1b, and Il-6 in the colon. When
comparing colon homogenates of rats fed the control 10% SO
diet with those fed the SO–T7 diet, we observed no significant
differences in TNF-a, Il-1b, or Il-6 concentrations (Supplemental
Figure 1).
In vitro modulation of mast cell mediator release by EPA,
DHA, and rosiglitazone. Although rosiglitazone did not affect
degranulation as measured by release of b-hexosaminidase
(Figure 4A), $25 mM rosiglitazone (Figure 4D) did significantly
inhibit release of TNF-a. Rosiglitazone treatment did not affect
basal release of b-hexosaminidase or TNF-a in unstimulated
cells. Treatment with different concentrations of EPA and DHA
did not affect release of b-hexosaminidase in unstimulated and
48/80-stimulated cells (Figure 4B and 4C). Release of TNF-a,
however, was significantly reduced in DHA-treated phorbol 12-
myristate 13-acetate/calcium ionophore–stimulated cells (Figure
4F), but not in EPA-treated cells (Figure 4E). Basal TNF-a
release did not change in EPA- or DHA-treated cells.
Discussion
Internet-based IBS patient groups and forums often discuss the use
of LCPUFAs as a treatment option, and LCPUFA preparations
FIGURE 1 Visceromotor response and mast cell degranulation status of rats treated with SO–T3 or SO–T7 or their respective control SO diets.
Visceromotor response data for SO–T3 and 7% SO control diets (A) and SO–T7 and 10% SO control diets (C) are presented as mean AUCs 6
SEMs, n = 8–10 rats. Means in the same treatment group labeled without a common letter differ, P , 0.05. Different toluidine blue staining
intensities of mucosal mast cells in the distal colon are presented as percentage of total stained cells. Comparisons were made between rats fed
SO–T3 (B) and SO–T7 diets (D) and their respective control groups. SO, soy oil; SO–T3, 4% soy oil and 3% tuna oil; SO–T7, 3% soy oil and 7%
tuna oil; WA, water avoidance.
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are sold online for this purpose. However, although preclinical
evidence exists for treatment efficacy in other disorders and
diseases, such evidence is completely lacking for IBS. Because
visceral hypersensitivity is a hallmark trait in the majority of
patients and is thought to be a pathophysiologic mechanism, we
evaluated the use of marine LCPUFAs to reverse poststress
visceral hypersensitivity, possibly via mast cell modulation, in the
rat maternal separation model. Our results suggest that LCPUFAs
do not reverse existing stress-induced visceral hypersensitivity in
this model.
Our previous animal experiments and a successful clinical
trial with the mast cell stabilizer ketotifen indicated that mast
cells may be an attractive target in IBS therapy (16, 17, 26), and
others have shown that LCPUFAs are capable of modulating
mast cell mediator release (21–23). In search of nutritional
routes to modulate mast cell activation, and fueled by internet
FIGURE 2 Dietary LCPUFA-mediated changes in rat erythrocyte membrane FA composition. Relative content of EPA (A, D), DHA (B, E), and
AA (C, F) in the erythrocyte membranes of rats fed SO–T3 (A, B, C), SO–T7 (D, E, F), or control SO diets. Data are presented as mean
percentages EPA, DHA, or AA of total FAs6 SEMs, n = 8–10 rats. ***Different from control diet, P, 0.001. AA, arachidonic acid; LCPUFA, long-
chain polyunsaturated fatty acid; SO, soy oil; SO–T3, 4% soy oil and 3% tuna oil; SO–T7, 3% soy oil and 7% tuna oil.
FIGURE 3 Visceromotor response and mast cell degranulation status of rosiglitazone-treated rats plus PPARG target gene expression in
rosiglitazone-treated and SO–T7-treated rats. Visceromotor response data of rosiglitazone-treated rats are presented as mean AUCs6 SEMs, n =
9–10. Means in the same treatment group labeled without a common letter differ, P , 0.05 (A). Toluidine blue staining intensities of mucosal
mast cells in the distal colon of rosiglitazone-treated rats are presented as percentages of total stained cells 6 SEMs, n = 9 (B). Relative mRNA
expression of the PPARG target genes lipoprotein lipase (C) and glycerol kinase (D) measured in rat adipose tissue of rosiglitazone-treated rats,
and lipoprotein lipase (E) and glycerol kinase (F) in the colonic tissue of SO–T7-treated rats. Relative mRNA expression data are means 6 SEMs,
n = 7–9. Different from vehicle treatment, *P , 0.05 and ***P , 0.001. SO, soy oil; SO–T7, 3% soy oil and 7% tuna oil; WA, water avoidance.
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attention, we evaluated the use of marine n–3 LCPUFAs in our
rat model. However, in contrast to earlier experiments in which
we successfully used the mast cell stabilizer doxantrazole (37)
and the histamine-1-receptor antagonist ebastine (17) to induce
reversal of poststress visceral hypersensitivity in maternal
separated rats, such reversal was not achieved with LCPUFA
treatment. As mentioned earlier, one of the mechanisms by
which n–3 LCPUFAs might elicit their beneficial effect is by
competing with AA for the 2-acyl position within the phospho-
lipid membrane, thus interfering with the production of
proinflammatory AA metabolites. Hence, an imbalance toward
n–6 FAs and their metabolites is thought to play a role in a
variety of inflammatory states. Importantly, an n–6/n–3 FA
imbalance was also shown in female IBS patients (8) and the
maternal separation model (38). In patients, the observed
imbalance correlated with increases in the AA metabolites
PGE2 and leukotriene B4. Because PGE2 and leukotriene B4
are biologically active at very low concentrations, profound
downstream effects can be induced by even small changes in AA
concentrations (39). Thus, similar to other diseases (19, 20),
neutralizing the n–6/n–3 FA balance might beneficially affect IBS
symptoms. In our experiments, incorporation of EPA and DHA
into the phospholipid membrane was assessed by monitoring the
FA profile of erythrocyte membranes. Although not specifically
evaluated here, it is known that other cell types, including those
of the immune system, also incorporate these FAs into their
cell membranes (3). Our data showed a profound increase in
membrane DHA and EPA concentrations at the expense of AA,
but without affecting poststress hypersensitivity to colorectal
distension. These results are in line with the study by Clarke et al.
(8), in which plasma AA concentrations did not correlate with
symptom severity in IBS patients. Combinedwith the present data
on LCPUFA supplementation, it may be concluded that increased
AA concentrations are not a probable cause for IBS symptoms.
Another possible mechanism by which LCPUFAs reportedly
modulate mast cells is via PPARG agonistic activity (1, 24, 25).
Consequently, our negative in vivo results on visceral hyper-
sensitivity reversal may suggest that the LCPUFA treatment
protocol insufficiently activated PPARG. Therefore, we used
the pharmacologic PPARG agonist rosiglitazone as a positive
control. Indeed, evaluation of the PPARG target genes lipoprotein
lipase and glycerol kinase indicated effective in vivo PPARGactivation
by rosiglitazone that was not observed in the high-dose LCPUFA
experiment. Nevertheless, rosiglitazone also did not affect visceral
hypersensitivity in our model. Celinski et al. (40) showed that the
same rosiglitazone dosage (30 mg rosiglitazone  kg21  d21) was
adequate to suppress inflammation and inflammatory cytokine
response in dextran sodium sulphate colitis. Thus, we suggest
that the inability of rosiglitazone to prevent a stress-induced
increase in sensitivity was unlikely to be because of insufficient
dosing. In relation to the tuna oil dosage scheme used in the
present study, it should be mentioned that we previously used
6% tuna oil and 4% SO to successfully prevent allergic
sensitization to cow milk protein in mice (41). Although in the
present experiments we used the same batch of tuna oil, an
important difference with the current protocol was the preven-
tive approach in the former experiments. Mice were fed the
LCPUFA-rich diet starting 2 wk before and during the cow milk
sensitization protocol. Because IBS patients are hypersensitive to
begin with, our aim in the present investigations was a treatment
strategy for reversal of symptoms instead of prevention. This
may have influenced the outcome of our in vivo investigations.
However, we did use a ‘‘prevention protocol’’ to test the efficacy
of rosiglitazone and this strategy was also ineffective.
The inability of LCPUFAs and rosiglitazone to affect visceral
hypersensitivity suggests that mast cell degranulation was not
impaired by these treatment protocols and this was confirmed by
toluidine blue staining of mucosal mast cells. This observation
was also supported by our in vitro experiments, in which
rosiglitazone, EPA, and DHA showed no effect on compound
48/80-induced degranulation of HMC-1 cells. Although these
negative results confirm our earlier observations on IgE-
mediated degranulation of LAD2 cells (23), they also add to
the existing controversy. Some studies report suppressive effects
of n–3 PUFAs on mast cell mediators and cytokine release
(22, 23, 42), whereas others report augmenting effects (43, 44).
Because our data on erythrocyte n–3 LCPUFA concentrations
confirm proper uptake of dietary LCPUFAs, the lack of effect on
mast cell–dependent visceral hypersensitivity suggests that their
in vivo effect on degranulation is limited. In contrast to the
FIGURE 4 In vitro effects of rosiglitazone, EPA, and DHA on a human mast cell line. Compound 48/80-induced b-hexosaminidase release by
HMC-1 cells preincubated with rosiglitazone (A), EPA (B), and DHA (C). PMA/CI-induced TNF-a release by HMC-1 cells preincubated with
rosiglitazone (D), EPA (E), and DHA (F). Data are means 6 SEMs, n = 3–9 per condition. Different from unstimulated controls, *P , 0.05, **P ,
0.01, and ***P, 0.001. Means within a group labeled without a common letter differ, P , 0.01. CI, calcium ionophore; HMC-1, human mast cell
line 1; PMA, phorbol 12-myristate 13-acetate.
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negative results on degranulation, we did observe in vitro
inhibitory effects on TNF-a release, with moderate modulation
by EPA and DHA, and strong inhibition by rosiglitazone.
Because mast cells are a major source of TNF-a in the intestine
(35), we expected to confirm these inhibitory effects in vivo.
However, when comparing TNF-a content of colon homoge-
nates, there was no significant difference between vehicle and
rosiglitazone treatment groups, suggesting that rosiglitazone did
not alter TNF-a production in vivo. However, because we used
whole-colon homogenates, relatively small differences may have
been rendered undetectable. Irrespective of this, at present there
are no indications that TNF-a plays a role in this rat model.
On the internet, LCPUFAs are offered as a possible treatment
option for IBS, but preclinical studies on efficacy are lacking. To
our knowledge, this rat study is the first to evaluate the possible
effect of LCPUFAs on an important pathophysiologic mecha-
nism of this disorder. In summary, this study shows that neither
the increased intake of n–3 LCPUFAs nor the pharmacologic
activation of PPARG can modulate poststress visceral hyper-
sensitivity in maternally separated rats. These results should not
be regarded as definitive proof that LCPUFA supplementation in
IBS will be ineffective, but more extensive investigations are
required to strengthen that conclusion. Our results do, however,
indicate that current claims should be regarded with caution.
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